## Ergebnisse aus IMMUNEBRIDGE für Modellierungskonsortien

Stand 31.07.22

## Daten ausfolgenden Bestandskohorten konnten eingeschlossen werden:

Tabelle 1 Zum 15.07. eingeschlossene Teilnehmer in teilnehmenden Bestandskohorten

	Erhebung IB finanziert	Art der Kohorte	Regionen	N aktuell	Vorhandene Untersuchungen	Vorhandene Datenitems	Einschränkungen
MuSPAD	Nein	Populationsbasiert von 2020, Einwohnermeldeämter	Magdeburg	1043	N-Ak, S-AK , S-IGRA	MDS vorhanden, Vorbefunde aus 2 Erhebungen	>18
MuSPAD	Nein	Populationsbasiert von 2020, Einwohnermeldeämter	Aachen	870	N-Ak, S-AK, S-IGRA	MDS vorhanden, Vorbefunde aus 2 Erhebungen	>18
MuSPAD	Ja, teilweise	Populationsbasiert von 2020, Einwohnermeldeämter	Hannover	1111	N-Ak, S-AK	MDS vorhanden, Vorbefunde aus 1 Erhebung	>18
NAKO	Nein	Populationsbasiert von 2016	18 Standorte Deutschlandweit	2557	N-Ak, S-AK	Alter, Sex	>18
Heinsberg	Nein		Heinsberg	579	N-Ak, S-AK	Alter, Sex, Vorbefunde aus 4 Erhebungen	
STAAB	Nein	Populationsbasiert	Würzburg	639	N-Ak, S-AK	MDS vorhanden, Vorbefunde aus 2 Erhebungen	>18
Dresden	Ja	Schulbasiert	Dresden	77	N-Ak, S-Ak	MDS vorhanden	12-17
Total				6886			

## Charakteristika der Teilnehmer

		MuSPAD	NAKO	Heinsberg	STAAB	Dresden	Total
Total		3025	2619	1434	660	76	6886
Sex	Female	1820 (60,2%)	1353 (51,7%)	764 (53,5%)	258 (53,2%)	59 (67,8%)	3764 (56,1%)
	Male	1205 (39,8%)	1263 (48,3%)	665 (64,5%)	227 (46,8%)	28 (32,2%)	2943 (43,9%)
Age, mean							
	0-4			1 (0,2%)			1 (0,02%)
	5-11			14 (2,4%)			14(0,2%)
	12-17			15 (2,6%)		76 (100%)	91 (1,4%)
	18 - 29	123 (4,1%)	83 (3,2%)	58 (10%)			264 (3,9%)
	30-34	158 (5,2%)	140 (5,4%)	28 (4,8%)			324 (4,8%)
	35-39	143 (4,7%)	124 (4,7%)	34 (5,9%)	7 (1,4%)		304 (4,5%)
	40-49	349 (11,5%)	335 (12,8%)	55 (9,2%)	63 (13%)		789 (11,8%)
	50-59	765 (25,3%)	741 (28,3%)	131 (22,7%)	138 (28,5%)		1749 (26,1%)
	60-64	382 (12,6%)	393 (15%)	68 (11,8%)	80 (16,5%)		914 (13,6%)
	65-79	945 (31,2%)	803 (30,7%)	140 (24,6%)	188 (38,8%)		2046 (30,5)
	>80	160 (5,3%)		34 (5,8%)	9 (1,9%)		203(3,1%)
Education (of	Higher education	1283 (59,4%)			234 (48,3%)	62 (74,2%)	1682 (51%)
parents for <18)	certificate	1283 (39,470)			254 (48,5%)	02 (74,270)	1002 (51%)
	10 <sup>th</sup> grade	512 (23,7%)			150 (30,9%)	13 (15,7%)	744 (22,6%
	9 <sup>th</sup> grade	165 (7,6%)			92 (19%)		400 (12,1%)
	No certificate	5 (0,2%)			4 (0,8%)		232 (7%)
	Other	194 (9%)			5 (1%)	6 (7,2%)	236 (7,2%)
Comorbidities							
	Hypertension	769 (35,4%)			252 (52%)		1266 (38,1%)

	Diabetes	138 (6,3%)	43 (8,9%)	223 (6,7%)		
	Cardiovascular	287 (13,2%)	125 (26%)	370 (13%)		
	Lung	208 (9,6%)	70 (14,4%)	348 (10.5%)		
	Immunodeficiency	140 (6,4%)	14 (2,9%)	189 (5,7%)		
	Cancer with Chemotherapy	64 (2,9%)	24 (5%)	114 (3,4%)		
Flu vaccination		1305, (60%)	258 (56,3%)	1968 (59%)		
Smallpox vaccination		792, 36,4%				

## Ergebnisse Antikörperuntersuchungen und IGRA

		MuSPAD			NAKO		Heinsberg		STAAB		nach K (cohort	open, stra (weights)				
		S-Ak (%)	N- Ak(%)	IGRA- S (%)	S-Ak (%)	N- Ak(%)	S-Ak (%)	N-Ak(%)	S-Ak (%)	N- Ak(%)	S-Ak (%)	95%- CI	N- Ak(%)	95%- CI	IGRA- S (%)	95%- CI
Total		2773, 99,4%	1004, 36%	677, 65,6%	2518, 98,6%	1094, 42,8%	565, 97,6%	334, 57,6%	633, 99%	268, 41,9%						
Total (altersgewichtet)		99,4%	37,4%	65,2%		47,1%		59,3%		44,6%	99,1%	98,7- 99,3	44,9%	43,4- 46,4	65,2%,	61-68
Sex																
	Female	1667, 99,3%	615, 36,5%	450, 67,8%	1298, 98,7%	550, 41,7%	315, 97,8%	178 (55,3%)		99, 40%	99%	98,5- 99,4	44,2%	42,2- 46,3	69,9%	65- 74%
	Male	1104, 99,5%	388, 34,9%	226, 61,4%	1217, 98,5%	544, 44%	250, 96,9%	156 (60,5%)		98, 45%	99%	98,5- 99,4	45,8%	43,5- 48,2	56,4%	49-63
Age			,	,	,		,	, ,				,				
	0-4						1	1								
	5-11						10 (71%)	8, 57%								
	12-17						16 (100%)	7, 43%			97,8%	92-99	62,6%	52-72		
	18 - 29	116, 100%	53, 45%	37, 74%	82, 98,8%	47, 56,6%	57 (98,3%)	40, 69%			99,6%	97- 100	53,8%	48-60	74%	60-84
	30-34	151, 99,3%	70, 46%	57, 76%	137, 99,3%	66, 47,8%	27, 96,4%	14, 50%			99,4%	98- 100	46,9%	42-53	75%	65-83
	35-39	137, 100%	67, 49%	55, 76%	117, 97,5%	75, 62,5%	34, 100%	26, 77%	7, 100%	5, 71%	99%	97- 100	57,3%	52-63	77%	66-85
	40-49	319, 99%	151, 47%	101, 77%	317, 97,8%	189, 58%	54, 98,2%	36, 65%	59, 98,3%	36, 60%	98,5%	97-99	54,3%	51-58	77%	69-84
	50-59	688, 99,1%	256, 37%	149, 76%	710, 98,6%	317, 44%	129, 98,5%	88, 67%	132, 99,3%	65, 48,9%	98,8%	98-99	42,8%	40-45	76%	69-82
	60-64	350, 99,7%	123, 35%	72, 66%	380, 98,5%	162, 44%	65, 95,6%	38, 56%	76, 98,7%	25, 32,5%	99,1%	98- 100	38,8%	36-42	68%	57-75
	65-79	857, 99,3%	249, 28,9%	160, 54%	775, 98,5%	238, 30,4%	137, 97,9%	60, 43%	177, 99,4%	63, 35,4%	99,2%	99- 100	31,3%	29-33	54%	49-60
	>80	155, 99,4%	35, 22,4%	46, 45%	30,370	30,170	34, 100%	15, 44 %	9,	3, 33%	99,5%	99- 100	26,6%	20-33	44%	35-54
		,	,													
Comorbidities																

Hypertension	1364,	34,2%	200,			98,8%,	89,	99,2%	98,3-	32,5%	29,4-	55,7%	60,8-
	99,4%		61,7%			239	36,8%		99,7		35,7		68,4
Diabetes	131,	36,	34,			38,	11,	98,3%	92-	26,7%	19,9-	44,9%	32-
	99,24%	27,1%	48,6%			97,4%	28,2%		99,7		34,8		58,3
Cardiovascular	277,	92,	73,			118,	45,	99,8	98,9-	30,2%	24,5-	57%	46-
	99,6%	36,4%	59,8%			100%	38,1%		99,9		36,7		66,8
Cancer	62	20,	11,			23,	8,	99,4%	98,9-	29,2%	20-	45,5%	24-
	100%	32,3%	55%			95,8%	33,3%		99,6		40%		68,6
Lung Disease	197,	62,	48,			70,	35,	99,5%	97,9-	34%	28-41	52%	40-
	99,5%	31,3%	51,6%			100%	50%		99,9				63,5
Immunesuppresion	136,	48,	28,			13,	6,	99,2%	97-	31,8	24,7-	54,9%	37-71
	99,3%	35%	62,2%			100%	46,2%		99,8		39		